# Edge Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/edge-medical

- Industry: Healthcare IT
- Headquarters: Shenzhen, China
- Website: www.edgemed.cn
- Total disclosed funding: $293M
- Latest round: Series C (Nov 6, 2021)
- Investors on record: 20

## About

Based in Shenzhen, China and established in 2017, Shenzhen Edge Medical Co., Ltd., trading as Edge Medical, operates as a smart surgical system developer that focuses on designing, developing and commercializing surgical robots. In May 2018, The company manufactured and presented its first robot prototype. In January 2026, Edge Medical raised HKD 1.2 billion in an IPO, selling 27.72 million shares at HKD 43.24 per share at Hong Kong Exchanges and Clearing (HKEX), under the ticker "2675".


The company provides smart robot-assisted surgical system. The company develops edge medical robotics technology, such as medical engineering, robot kinematics and mechanical sensing. The product of the company includes Porous surgical robot and single-hole surgical robot. The company adopts artificial intelligence technology, visualization technology and multi-dimensional sensing technology.

The company generates revenue by doing R&D and providing surgical robots and other related products.

## Funding rounds

- Series C, Nov 6, 2021, $200M — OrbiMed Advisors, Hong Shan, Temasek Holdings, Sage Partners, Boyu Capital, Mirae Asset Venture Investment, LYFE Capital, 3H Health Investment, Firstlight Capital, Octagon Capital Investments, Greater Bay Area Homeland Investments Limited, Panorama Capital, Mixed Reform Fund, Lingang Lanwan Fund
- Series B, Jan 22, 2021, $93M — LYFE Capital, Vertex Ventures China, Alwin Capital, BioTrack Capital, Poly Capital, 3H Health Investment, Hangzhou Kangji Medical Instrument Co., Ltd, Panorama Capital
- Series A, Apr 1, 2020 — Legend Star, Poly Capital, 3H Health Investment

## Investors

- Legend Star (https://capitalatlas.ai/funds/legend-star) — Series A
- Poly Capital (https://capitalatlas.ai/funds/poly-capital) — Series A, Series B
- 3H Health Investment (https://capitalatlas.ai/funds/3h-health-investment) — Series A, Series B, Series C
- LYFE Capital — Series B, Series C
- Vertex Ventures China (https://capitalatlas.ai/funds/vertex-ventures-china) — Series B
- Alwin Capital — Series B
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series B
- Hangzhou Kangji Medical Instrument Co., Ltd — Series B
- Panorama Capital — Series B, Series C
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- Hong Shan — Series C
- Temasek Holdings — Series C
- Sage Partners (https://capitalatlas.ai/funds/sage-partners) — Series C
- Boyu Capital (https://capitalatlas.ai/funds/boyu-capital) — Series C
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series C
- Firstlight Capital — Series C
- Octagon Capital Investments (https://capitalatlas.ai/funds/octagon-capital-investments) — Series C
- Greater Bay Area Homeland Investments Limited (https://capitalatlas.ai/funds/greater-bay-area-homeland-investments-limited) — Series C
- Mixed Reform Fund — Series C
- Lingang Lanwan Fund — Series C